Resistance to ␤-lactams and quinolones in two isogenic Enterobacter cloacae isolates was studied. One was susceptible to cefoxitin and amoxicillin-clavulanate. The other one showed its natural ␤-lactam resistance pattern. Both isolates had a nonfunctional AmpR regulator. However, within the second one, the presence of a plasmid carrying ampR and qnrA1 allowed reversion to the wild-type ␤-lactam resistance phenotype and decreased susceptibility to fluoroquinolones.
The production of the chromosomally encoded AmpC ␤-lactamase in many members of the family Enterobacteriaceae, including Enterobacter cloacae, Citrobacter freundii, Providencia stuartii, Serratia marcescens, Morganella morganii, and Yersinia enterocolitica, is induced by the presence of some ␤-lactams, resulting in a broad range of resistance to this family of antibiotics (1, 2) . This induction is due mainly to the presence of AmpR, a regulator belonging to the LysR family.
The production of AmpC is closely related to the recycling of peptidoglycan. This process implies the activity of the transmembrane permease AmpG and the cytoplasmic amidase AmpD, a protein involved in the turnover and recycling of muropeptides (6, 8, 13) . During normal bacterial growth, in the absence of ␤-lactams, anhydromuropeptides released from the bacterial peptidoglycan in the periplasm are imported into the cytoplasm by AmpG and hydrolyzed by the amidase AmpD, and the resulting components are used for the synthesis of murein precursors. One of these precursors, the UDP-MurNac pentapeptide (uridine-pyrophosphoryl-N-acetylmuramyl-L-alanyl-Dglutamyl-meso-diaminopimelic acid-D-alanyl-D-alanine), binds to AmpR, causing AmpR to assume a configuration which does not activate the ampC promoter, thereby resulting in a low level of ampC expression. In contrast, in the presence of ␤-lactam, anhydromuropeptides accumulate in the cytoplasm, displacing UDP-MurNac pentapeptide from its AmpR-binding site. AmpR thereby assumes an active configuration and enhances ampC expression (7) .
Two E. cloacae isolates, Ecl-834 and Ecl-835, were obtained from the same urine sample from a patient with urinary tract infection. Antibiotic susceptibility was tested by disk diffusion according to the Clinical and Laboratory Standards Institute guidelines for Enterobacteriaceae (3). For selected antibiotics, MICs were determined by Etest (Table 1) . Both isolates were resistant to ampicillin, cephalothin, and cefuroxime and showed synergy of cefotaxime, ceftazidime, cefepime, and aztreonam with amoxicillin-clavulanate, suggesting the production of an extended-spectrum ␤-lactamase (ESBL). Ecl-834 was also resistant to cefoxitin, amoxicillin-clavulanate, and trimethoprimsulfamethoxazole and showed induction of resistance to aztreonam by imipenem. However, Ecl-835 was susceptible to cefoxitin, amoxicillin-clavulanate, and trimethoprim-sulfamethoxazole and did not show induction of resistance to aztreonam by imipenem (Fig. 1) . By Etest, the ciprofloxacin MIC was 1.5 and 0.25 g/ml for Ecl-834 and Ecl-835, respectively (Table 1) .
In order to determine whether the two isolates were isogenic, enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR) was performed as previously described (17) . We included in the ERIC-PCR analysis an unrelated E. cloacae strain (harboring qnrA1) as control. Amplified PCR products were analyzed by agarose gel electrophoresis. The banding patterns revealed genomic identity between the two isolates ( Fig. 2) .
Analytical isoelectric focusing of the crude cell extract (15) showed in both isolates the same ␤-lactam-hydrolyzing bands, one of pI 8.0, compatible with the presence of one ESBL (12, 14, 16) , and another of pI Ͼ8.5, compatible with the chromosomal AmpC ␤-lactamase (4). bla CTX-M-9 was detected by PCR amplification (16) , and direct sequencing of amplicons showed 100% sequence identity with bla CTXM-9 in both isolates. The pI and susceptibility test results showed that production of the chromosomal ampC ␤-lactamase in Ecl-835 could be detected by isoelectric focusing but not by disk diffusion, suggesting that AmpC was produced at a low level in this isolate.
To elucidate why Ecl-834 and Ecl-835 exhibited different pattern of chromosomal ␤-lactamase production, ampC and its regulatory gene ampR were amplified and sequenced using primers designed based on homologous regions of ampC and ampR sequences from E. cloacae. There was no difference in the ampC or ampR sequences between the two isolates. However, in comparisons of these ampC and ampR sequences with those from E. cloacae isolates with a normal resistance phenotype, including (i) one from public databases and (ii) one obtained from our collection, an insertion of a C between bases 92 and 93 of the ampR gene was found. This insertion is predicted to generate a new stop codon 18 bp downstream, resulting in a putative peptide comprising 37 amino acids instead of the 291 that form the native AmpR protein. ) between orf513 and the second copy of the 3Ј conserved sequence, which include the sulI gene (18) . To determine whether this was true also for the integron in strain Ecl-834, PCR amplification and sequencing of the genes located downstream of qnrA1 revealed an ampR DHA-1 gene in this strain, as reported for integrons In36 and In37. We speculated that this gene conceivably could complement the defective chromosomally encoded ampR gene in strain Ecl-834.
In order to prove that in strain Ecl-834 the plasmid-encoded ampR DHA-1 substituted for the defective chromosomal ampR gene, the ampR DHA-1 gene was cloned using a pGEM-T Easy vector system (Promega Corp., Madison, WI), and the resulting recombinant plasmid was electroporated into Ecl-835 electrocompetent cells. The resulting Ecl-835 (pAMPR DHA1 ) strain showed the same antibiogram disk diffusion pattern as Ecl-834 except for trimethoprim-sulfamethoxazole, to which the derivative remained susceptible (Fig. 1) . In addition to this assay, plasmid curing was performed with Ecl-834 and acridine orange in order to demonstrate that the plasmid containing the qnrA1-ampR genes was responsible for conferring on the wildtype strain the phenotype of resistance to ␤-lactams. Ecl-834 was growth in brain heart infusion medium with 80 g/ml acridine orange (Sigma-Aldrich Inc., Steinheim, Germany) for 24 h with shaking at 42°C. Cells which had lost the plasmid containing the qnrA1-ampR DHA-1 genes and the plasmid with the ESBL gene were selected by negative selection-replica plating on LB with cefoxitin (100 g/ml) and ampicillin (100 g/ml). The Ecl-834 derivatives that had lost the plasmid or the integron containing the qnrA1-ampR DHA-1 genes but not the bla CTX-M-9 gene (Ecl-834 CQR) exhibited the same antibiogram as did Ecl-835. The Ecl-834 derivatives that had lost both qnrA1-ampR DHA-1 and the bla CTX-M-9 gene (Ecl-834 CQRE) were susceptible to all antibiotics tested (Fig. 1) . Overall, these experiments proved that the wild-type resistance phenotype of Ecl-834 is due to the presence of the plasmid-mediated ampR DHA-1 .
We next sought to assess how the presence of the plasmid bearing the qnrA1-ampR genes could affect quinolone and fluoroquinolone resistance in these isolates. By Etest, the MIC of nalidixic acid was Ն256 g/ml for both isolates, whereas the MIC of ciprofloxacin was 1.5 and 0.25 g/ml for Ecl-834 and Ecl-835, respectively, representing a sixfold difference (Table  1) . PCR amplification and sequencing of the quinolone resistance-determining region of the gyrA, gyrB, parC, and parE genes, as previously described (11), showed in both isolates a single amino acid change in gyrA, Ser833Phe, which previ- VOL. 50, 2006 NOTES 3177 ously has been described for E. cloacae as responsible for resistance to nalidixic acid (5). qnrA1, including its promoter, was cloned into a pGEM-T Easy vector system (Promega). Electroporation of the resulting recombinant plasmid into Ecl-835 electrocompetent cells yielded strain Ecl-835 (pQNRA1). This strain showed the same ciprofloxacin MIC, 1.5 g/ml, as strain Ecl-834, demonstrating that QnrA1 is able to increase the ciprofloxacin MIC sixfold (Table 1) .
In our laboratory, we have found that around 1.5% of isolates of E. cloacae do not express phenotypically the intrinsic resistance of this species to ␤-lactams (unpublished data). Previous works have described the constitutive expression of AmpC in E. cloacae strains due to chromosomal ampR mutations (9, 10). To our knowledge, this work reports the first isolation of a clinical strain defective for AmpR production due to chromosomal ampR mutation which in vivo reverts to its presumed ancestral phenotype as a result of the acquisition of an exogenous ampR gene embedded in a plasmid which also carries a qnrA1 gene.
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